Summary & Overview
HCPCS J7622: Beclomethasone Inhalation Solution, Compounded Unit Dose
HCPCS Level II code J7622 designates beclomethasone inhalation solution as a compounded, unit-dose product billed per milligram. The code captures a compounded respiratory corticosteroid formulation intended for inhalation delivery through durable medical equipment, typically supplied for use in home or outpatient settings. Nationally, accurate coding of compounded inhalation solutions affects pharmacy dispensing, DME billing, and payer adjudication for respiratory disease management.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inhaled corticosteroid therapy, coding and billing considerations specific to a compounded unit-dose form, and what to expect from payer coverage practices. The publication summarizes benchmark payment perspectives, common modifier usage when available (input provided), and notes on sites of service relevant to DME-delivered inhalation treatments.
The report is aimed at billing managers, pharmacy directors, and revenue cycle staff who need a clear reference for coding compounded inhalation medications under HCPCS Level II. Data not available in the input will be identified where applicable in the full publication.
Billing Code Overview
HCPCS Level II code J7622 describes beclomethasone, inhalation solution, compounded product, provided in unit dose form and billed per milligram. The service type is compounded inhalation medication administration via durable medical equipment, reflecting a pharmacy- or DME-delivered respiratory corticosteroid intended for inhalation therapy. The typical site of service is home or other outpatient settings where DME is used to deliver inhalation therapy. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with persistent asthma or corticosteroid-responsive airway inflammation who requires inhaled corticosteroid therapy delivered via a nebulizer. The compounded J7622 product (beclomethasone inhalation solution, unit dose, per mg) is prepared by a pharmacy and administered through durable medical equipment (nebulizer) in an outpatient infusion center, long-term care facility, or home health setting when metered-dose inhalers or dry powder inhalers are unsuitable (for example, in young children, patients with coordination problems, severe airflow obstruction, or during hospitalization for acute exacerbation requiring nebulized corticosteroid therapy). The clinical workflow includes: prescription by a pulmonary specialist, pediatrician, or hospitalist specifying dose in milligrams; pharmacy compounding and unit-dose labeling; documentation of administration via DME (nebulizer) by nursing or respiratory therapy staff; recording lot/batch and mg dispensed; and billing the compounded inhalation solution using J7622 with appropriate modifier(s) reflecting circumstances of service (for example, acute care, no charge, or multiple procedure situations).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard billing indicator | Use when no special reporting modifier applies. |